Somatic hypermutation profiles in stereotyped IGHV4-34 receptors from South American chronic lymphocytic leukemia patients.

Andrea Krzywinski, Irma Slavutsky, Pablo Oppezzo, Miguel A Pavlovsky, Astrid Pavlovsky, Raimundo Bezares, Evangelina Agriello, Lorena Zanella, Cecilia Lang, Carmen Stanganelli, Camila Galvano, Claudia Mardaraz, Juana Cabrera, Victoria Remedi, María Elena Márquez, Claudia Ortega, Davi Coe Torres

Journal: Annals of hematology 2022;101(2):341-348

PMID: 34713310

Abstract

Chronic lymphocytic leukemia (CLL) is the most common mature B-cell neoplasm in the West. IGHV4-34 is one of the most frequently used genes in CLL patients, which usually display an indolent outcome. In this study, we explored the mutational profile of CLL patients expressing IGHV4-34 within different stereotypes and their association with prognostic factors and clinical outcome. A multi-institutional cohort of unselected 1444 CLL patients was analyzed by RT-PCR and bidirectional sequencing. Cytogenetics and molecular cytogenetics analyses were also performed. We identified 144 (10%) IGHV4-34 expressing cases, 119 mutated (M), 44 of them with stereotyped B-cell receptors. Subset #4 was the most frequent (56.8% of cases) followed by subsets #16 (13.6%), #29 (6.8%), and #201 (2.3%), with different distribution among countries. Analysis of somatic hypermutation profile showed significant differences among stereotyped subsets for G28>D/E, P45>S, E55>Q, and S64>I changes (p < 0.01) and high frequency of disruption of the glycosylation motif in the VH CDR2 region. All stereotyped IGHV4-34 cases showed normal karyotypes. Deletion 13q14 as a sole alteration was present in 42.8% of stereotyped cases with a different distribution among subsets. A shorter time to first treatment was found in non-stereotyped vs. stereotyped M-IGHV4-34 patients (p = 0.034). Our results add new information supporting the importance of recurrent amino acid changes at particular positions, contributing to refine the molecular characterization of South American CLL patients.

© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Address: División Patología Molecular, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina. [email protected].; Instituto Nacional de Câncer, Río de Janeiro, RJ, Brazil.; Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.; Chronic Lymphocytic Leukemia Laboratory, Institut Pasteur de Montevideo, Montevideo, Uruguay.; Instituto Venezolano de Investigaciones Científicas, Caracas, Venezuela.; Hospital Maciel, Administración Servicios de Salud del Estado, Ministerio de Salud, Montevideo, Uruguay.; División Patología Molecular, Instituto de Investigaciones Hematológicas, Academia Nacional de Medicina (ANM), Pacheco de Melo 3081, 1425, Buenos Aires, Argentina.; Centro de Hematología Pavlovsky, Buenos Aires, Argentina.; Laboratorio de Genética de Neoplasias Linfoides, Instituto de Medicina Experimental, CONICET-ANM, Buenos Aires, Argentina.; Laboratorio de Especialidades Bioquímicas, Bahía Blanca, Argentina.; Hospital General de Agudos Teodoro Álvarez, Buenos Aires, Argentina.

Link outs

Subscription / membership required

Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.